



Review on an Ayurvedic Polyherbal Formulation for Rheumatoid Arthritis

Padmashree Rajendra Mokashi¹, Mr. Abhishek V. Desai², Dr. Nilesh B. Chougule³

¹ A/P- Ichalkaranji, Tal. – Hatkangale, Dist.-Kolhapur, Pin code- 416115.

Email Address- padmashreemokashi@gmail.com

² Corresponding Author

³ Co-Author

Ashokrao Mane Institute of Pharmacy, Ambap-416112

ABSTRACT:

A complex autoimmune illness with an unclear etiology, rheumatoid arthritis (RA) primarily affects the joints, though it can also appear extra-articularly. A multidisciplinary approach is necessary for effective RA care because of its complexity, which stems from a pathophysiological process that is still poorly understood. It is a chronic, debilitating autoimmune disease that damages the bone and cartilage surrounding joints and causes systemic inflammation. Being a systemic disease, it can impact internal organs including the heart, lungs, and eyes as well as the entire body. Despite the fact that many synthetic medications are utilized as standard treatments for rheumatoid arthritis, their side effects can jeopardize the effectiveness of the therapeutic approach. Unfortunately, there is now no proven medication that can effectively treat rheumatoid arthritis; instead, contemporary medicine can only address its symptoms, which include joint discomfort and inflammation. The pain and inflammation in the joints can be reduced by using the plants and herbs in different ways. Traditional medicine uses a wide variety of herbal medications, and fundamental scientific study has shown that these treatments are effective in treating arthritis. Through the suppression of inflammatory biomarkers with fewer adverse effects and the provision of information for future research into natural drug therapy for rheumatoid arthritis, the current review has elaborated on a selection of traditionally used herbal medicinal plants with phytoconstituents that possess anti-inflammatory activity.

Keywords: Rheumatoid Arthritis, Herbal Plants, Joints.

INTRODUCTION:

Joint synovial inflammation and progressive bone and cartilage degradation leading to progressive immobility are hallmarks of rheumatoid arthritis (RA), a chronic inflammatory illness with an unclear etiology [1]. Inflammation of the joints, or arthritis, is one of the oldest known disorders that affect people of all ages. Approximately 20% of the population in India suffers from arthritis [2].

There is no hereditary component to rheumatoid arthritis. Scientists think that certain individuals are predisposed to the illness due to their genetic makeup. Rheumatoid arthritis does not always develop in people with these genes. Usually, an illness or environmental factor acts as a "trigger," activating the genes. When this trigger is present in the body, the immune system responds incorrectly. The immune system begins to produce substances that harm the joint instead of protecting it. As a result, rheumatoid arthritis may develop. It is an autoimmune disease, which means that the body's immune system unintentionally attacks healthy tissues. Normal joints have a relatively thin lining with few blood vessels, but rheumatoid arthritis joints have a thick lining filled with white blood cells. Chemicals such as interleukin-1 (IL-1) and tumor necrosis factor alpha (TNF-alpha), which cause pain, joint swelling, and joint destruction, are secreted by white blood cells. New cytokines such as IL-17 and IL-18 have been found recently. These cytokines cause the chondrocytes and synovial fibroblasts in the surrounding articular cartilage to release enzymes that break down collagen and proteoglycans, causing tissue degradation and the involvement of RANK ligand (RANKL) in the pathophysiology of chronic arthritis [3,4]. Although arthritis may impact anyone at any age, it is most common between the ages of 25 and 50, peaking between the ages of 40 and 50. There are roughly 100 different kinds of arthritis, but the most prevalent ones include juvenile arthritis, osteoarthritis, rheumatoid arthritis, ankylosing spondylitis (AIS), and systemic lupus erythematosus [5].

Herbal Therapy for the Treatment of Arthritis:

Since ancient times, herbal medicines have been used to treat a wide range of illnesses, and it is not hyperbole to claim that the usage of herbal medications predates humanity [6]. Herbal remedies are created using the therapeutic expertise of generations of doctors who have been working in the traditional medical system for hundreds of years [7]. Because the medications that are now on the market are either very costly or have specific negative effects, researchers are now very interested in therapeutic substances that are produced from plants [8]. Herbal plants, which are abundant worldwide and provide therapeutic compounds for the prevention and treatment of a wide range of illnesses, are a gift from nature [9]. Over 80 percent of people worldwide utilize herbal medications for their basic medical needs, according to the WHO. Since the beginning of civilization, herbal remedies have been a part of human society's efforts to fight disease [10]. These herbal plants' medicinally significant components are chemical components that give the body the required physiological effect [11].

Herbal remedies have been used in India's officially recognized alternative health systems, including Ayurveda, Unani, Sidha, Homeopathy, and Naturopathy, since ancient times [12]. More than 2500 plant species are now utilized as herbal medicines in India. Herbal remedies have been utilized for almost 3,000 years, either directly as traditional medicine or indirectly in the manufacturing of modern pharmaceuticals [13]. Therefore, one may be able to find novel, more affordable, and effective medications by using the knowledge of traditional botanicals [14].

Polyherbal Formulations for Arthritis:

In patients with acute or chronic RA, analgesics and NSAIDs can help reduce pain and inflammation [15]. Even though there are treatments for RA, new strategies are being developed to balance the known advantages and possible hazards because of the possibility of irreversible organ damage or negative effects [16]. Currently, safer and more effective medications are being produced from eastern sources to treat RA. To lessen these negative effects and boost the positive ones, a wide range of herbal extracts and medicines, including polyherbal combinations, are made [15].

The polyherbal combination known as Rheum off Gold is frequently suggested by Ayurvedic physicians to cure arthritis. Using a complete Freund's adjuvant (CFA)-induced arthritis model in Wistar rats, the anti-arthritis activity was verified. The arthritis index, paw thickness, and inflammatory indicators such as C-reactive protein, serum rheumatoid factor, and erythrocyte sedimentation rate (ESR) all significantly decreased in comparison to dexamethasone. The formulation might therefore have anti-arthritis qualities [17].

Rats were used to test an Unani polyherbal mixture for antiarthritic effects. Models of formaldehyde and CFA-induced arthritis were used to assess Manjoon Suranjan's anti-arthritis effectiveness. The information gathered indicated that the formulation has anti-arthritis properties [18]. Sudard was evaluated as a potent anti-arthritis polyherbal compound using Wistar rat models of arthritis caused by formaldehyde and adjuvants. At 150 mg/kg and 300 mg/kg p.o. doses, the formulation has anti-inflammatory and anti-arthritis effects [19].

Tongbiling (TBL-II) possesses anti-arthritis qualities and was created by altering the Chinese herbal formulation of TBL. The formulation's anti-arthritis efficacy was examined in Wistar rats using a collagen-induced arthritis model. The TNF- α and IL-1 β levels were observed to be significantly reduced at 100 and 300 mg/kg p.o. Consequently, the anti-arthritis potential of the formulation was established [20].

For the past century, the Chinese herbal combination HLXL has been utilized to treat arthritis and inflammation. Additionally, utilizing a CFA model in rats, the anti-arthritis properties of HLXL herbal formulation were assessed following some adjustments. The polyherbal preparation was found to have anti-arthritis activity by dramatically lowering TNF- α and IL- β levels as well as paw oedema [21].

Ganghwaljetongyeum's ability to treat RA in rabbit knee synovial membranes was investigated. HG82 cell growth was found to be significantly inhibited, indicating that the polyherbal formulation had anti-arthritis properties. Additionally, TNF- α , IL-10, and NO species were significantly reduced [15].

Epidemiology:

The World Health Organization (WHO) estimated that between 0.5 and 2% of adults worldwide suffer from RA, with a higher risk of developing the disease in North America and Europe than in Asia [22–24]. In India, between 0.28 and 0.7% of people have RA, and the prevalence is higher in rural areas than in urban areas [25–26]. The risk of having RA in adults is 1.7% (1 in 59) for men and 3.6% (1 in 28) for women. Patients with RA have a threefold higher overall mortality rate than the general population [26,27]. Accordingly, the survey data indicated that RA is more common in women than in men, meaning that women are two to three times more likely to get RA than men because of the drop in estrogen levels that occurs following menopause [27]. Additionally, depending on the severity of the disease and other genetic factors, the lifespan expectancy with RA disease might be lowered by up to 5–10 years [28, 29].

Etiological factors of rheumatoid arthritis:

Environmental factors, sex hormones, and genetic factors combine to trigger the immunological response [30]. The evolution of the current condition is believed to have been influenced by a number of variables. (1) Effects of sex and sex hormones: elderly women are three to four times more likely than men to develop RA [27]. In addition to its anti-inflammatory effects, estrogen suppresses NF- κ B signaling by upregulating the expression of κ B-Ras2, an NF- κ B inhibitor that further suppresses the genes of inflammatory mediators and lowers TNF- α , interleukins (IL-6), and other chemicals linked to arthritis [31]. Rheumatoid arthritis was caused by women's decreasing estrogen levels during the onset of menopause [32]. Oestrogen regulates metabolism, has anti-inflammatory effects, and aids in fat maintenance. The menopause decrease in oestrogen levels often causes arthritis. Pregnancy, the postpartum period, and the perimenopausal era are therefore times when RA is more prevalent in women [33]. Serum levels of BMD cells, IL-4, and IL-6 are also elevated by the hyperprolactinemia that causes auto-antibodies [34]. (2) Genetic factors: RA was 12–15% more common among monozygotic twins than in the general population, which is about 2–5% higher. This implies that STAT γ and signalling transducer polymorphisms exist in siblings [35, 36]. Rheumatoid arthritis is approximately 40–65% heritable, or genetically linked, due to mutations in the human leucocyte antigen (HLA) gene and other immune- and inflammatory-like interleukin (IL-4, IL-10) genes [35,37]. (3) The environment and additional elements: Numerous bacteria found in the environment, including Salmonella, Campylobacter, Porphyromonas gingivalis, Proteus mirabilis, and Mycoplasma organism, have caused RA [38]. Moreover, viruses including the rubella virus and Epstein-Barr virus (EBV) are the cause of RA [39]. Additionally, rheumatoid arthritis has been linked to changes in the makeup and function of the intestinal microbiome, meaning that patients with the disease have a less diverse gut microbiota than healthy people [40]. Because it causes the formation of RF factor, which is up to three times more prevalent in smokers than non-smokers, smoking is also one of the risk factors for rheumatoid arthritis [41, 42].

SYMPTOMS:

Joint discomfort and swelling, stiffness in the morning, sleep issues, exhaustion, weight loss, and a feeling of having the flu are some of the symptoms. Rheumatoid arthritis is diagnosed by looking for abnormal antibodies (IgG) in the blood, known as rheumatoid factor. An antigen-antibody complex is created when these react with antigen, resulting in pain and inflammation of the synovial membrane. The diagnosis must be confirmed by at least four of the seven criteria listed below, according to the American College of Rheumatology [43, 44].

- Morning stiffness around the joint that lasts at least 1 hour
- Arthritis of three or more joints for at least 6 weeks
- Arthritis of hand joints for at least 6 weeks
- Arthritis on both sides of the body for at least 6 weeks
- Rheumatoid nodules under the skin
- Rheumatoid factor presents in blood testing
- Evidence of rheumatoid arthritis on X-rays

The widespread occurrence of arthritis symptoms and their impact on social, professional, and physical activities can be depressing, leading to psychological aftereffects as anxiety, melancholy, and a sense of powerlessness [45]. Because RA might start with mild symptoms like achy joints or mild stiffness, it can be challenging to diagnose. When RA is active, the stiffness is usually at its worst in the morning. It may go on for an hour or two, or possibly the entire day. Since few other arthritic diseases exhibit stiffness for an extended period of time in the morning, this is a sign that a person may have RA [46].

In 1958, the American Rheumatism Association (ARA) initially proposed classification criteria for RA [47]. The American College of Rheumatology (ACR) updated the 1958 ARA criteria in 1987 [48].

Table 1: The 1987 revised ARA/ACR criteria for classification off rheumatoid arthritis.

Criterion	Simple title	Definition
1.	Morning stiffness	Stiffness in and around the joints in the morning that lasts for at least an hour before getting better. Three joints or more.
2.	3 or more joint regions with arthritis	A doctor has noticed simultaneous soft tissue swelling or fluid in certain areas (not only bone enlargement). Right or left PIP, MCP, wrist, elbow, knee, ankle and MTP joints are among the 14 potential locations.
3.	Arthritis of hand Joints	At least one wrist, MCP, PIP joint area that is inflamed (as previously described)
4.	Symmetric Arthritis	Joint areas [as specified in (2)] on both sides of the body may be involved simultaneously (bilateral involvement of PIPs, MCPs, or MTPs is permissible without total symmetry).
5.	Rheumatoid Nodules	A doctor's observation of subcutaneous nodules, over bony prominences, or extensor in juxta articular regions.
6.	Serum rheumatoid factor	Serum rheumatoid factor levels that are abnormal, or any test that yields a positive result in less than 5% of healthy control subjects.
7.	Radiographic Changes	Rheumatoid arthritis radiographic abnormalities on posteroanterior hand and wrist radiographs must include erosions or clear bone decalcification that is localised in or most noticeable around the affected joints (changes from osteoarthritis alone do not qualify).

RISK FACTORS FOR RA:

Genetic, environmental, and stochastic factors all contribute to RA, which is a complex disease [49]. According to scientific studies, the estimated hereditary risk for RA is almost 50% [50,51]. RA can be classified as either seropositive or seronegative based on the presence or absence of rheumatoid factor (RF) and ACPAs. There are also variations in the risk variables that are implicated [52,53]. The primary genetic factors linked to an ACPA-positive subtype are tyrosine phosphatase non-receptor type 22 (PTPN22) risk alleles [54,55], human leukocyte antigen D-related (HLA-DR) alleles [52], and genes related to tumor necrosis factor-receptor associated factor 1 and complement component 5 (TRAF1/C5) [56], whereas interferon regulatory factor 5 (IRF-5) is exclusive to the ACPA-negative subtype [57]. Environmental risk factors are crucial in managing RA since they are major contributors to population health. Smoking has been connected to the onset or aggravation of RA, just as other diseases. By chance, a study with a different goal discovered the first evidence linking smoking to an increased risk of RA [58]. It has since emerged as the most well-characterized risk factor for RA. Numerous studies have examined the dangerous compounds found in tobacco products, and the findings indicate that smoking sends out a certain signal. A specific subtype of RA may be triggered by smoking, which may be linked to a genetic context [59]. According to reports, smoking has no or very little influence on ACPA-negative RA [61] but has an impact on RF- or ACPA-positive RA [60]. Furthermore, smokers with HLA-DR Beta 1 shared epitope alleles have a significantly increased chance of developing ACPA-positive RA [62]. Passive smokers and the risk of having RA have not been found to be associated in any way [63].

One occupational exposure that affects RA is silica dust exposure. Patients with ACPA-positive RA are primarily affected by the reported correlation between silicosis and RA [64]. Rheumatoid pneumoconiosis, sometimes referred to as Caplan's syndrome, is an uncommon condition that occurs in RA patients who have developed silicosis as a result of prolonged exposure to silica [65].

Consumption patterns and dietary components have also been evaluated throughout time. RA is influenced by dietary factors, and studies have shown that vegetarian diets and fasting periods can help reduce the disease's progression. Additionally, limiting red meat and eating more fruit and oily fish may reduce the incidence of RA [66,67]. Coffee consumption may be a risk factor for RA because of its possible involvement in the development of RF [68]. Although further research is required to confirm this notion, a case-control study revealed that alcohol use may improve RA by lowering the risk of developing ACPA-positive RA [59]. A customized diet for each individual should therefore be taken into account.

One biological risk factor that could lead to the onset of RA is infection. According to a comparative cohort research, people with RA have a much higher incidence of joint, skin, and bone infections than those with non-inflammatory rheumatic disorders [69]. Furthermore, Lyme arthritis, a condition that shares many characteristics with RA, has also been linked to bacterial triggers [70].

A harmful bacterium called *Porphyromonas gingivalis* is the cause of periodontal disease. Due to its role in promoting osteoclast development and citrullination stimulation, there has been evidence of a connection between RA and periodontal disease [71].

The foundation for comprehending the intricacy of the biomolecular mechanisms that coordinate RA may be a thorough description of the interplay among environment, genes, and stochastic events.

PATHOPHYSIOLOGY OF RA:

Numerous theories have been proposed, despite the fact that the pathophysiological mechanisms behind RA remain incompletely understood. According to reports, immunological processes might take place years before joint inflammation symptoms appear; this is known as the "pre-RA phase" [72]. Modified self-antigens, including as immunoglobulin G (IgG), type 2 collagen, and vimentin, might result from the interplay between environmental influences and epigenetic changes on the genomic structure. Citrullination is a post-translational alteration that occurs when peptidyl arginine deiminases transform these proteins with arginine residues into citrulline [73,74]. Furthermore, cytokine production from joint conditions such as synovial hyperplasia or infections can result in joint inflammation and altered self-antigens [75].

The immune system can no longer identify citrullinated proteins (vimentin, type II collagen, histones, fibrin, fibronectin, Epstein-Barr nuclear antigen 1, α -enolase) as self-structures because of the susceptibility genes HLA-DR1 and HLA-DR4 [76]. Antigen-presenting cells (APCs) are activated dendritic cells that take up antigens in order to trigger an immune response. The entire complex moves to the lymph node, where CD4+ helper T cell activation occurs. Additionally, B cells in the lymph node's germinal Centre are stimulated by sequential and reciprocal impulses with T cells, a process known as costimulation in immunology.

The relationship between CD28 and CD80/86 is an example of costimulation [77,78]. At this stage, B cells develop into plasma cells that make autoantibodies based on the receptors of the precursor cells, undergo somatic hypermutation, or class-switch recombination, and begin to multiply [79]. Self-tissues and organs are unintentionally targeted by autoantibodies, which are proteins generated by an immune system that is no longer able to distinguish between self and non-self-components. RF and ACPA are the most extensively studied autoantibodies linked to RA. With an 85% testing specificity in RA patients, RF is an IgM antibody that targets the constant region, or Fc portion of IgG [80]. It also forms an immune complex that can pass through synovial fluid by joining forces with complement protein and IgG. By binding to citrullinated proteins and forming immune complexes that build up in the synovial fluid, ACPA more precisely targets RA [81].




Figure 2. Immunological processes in the pre-RA phase. ACPA, anti-citrullinated protein antibodies; APC, antigen-presenting cells; RF, rheumatoid factor.

Table 2: Traditionally used anti-arthritic plants

Scientific name	Family	Common name	Disease Treated	Part used	Dosage form	References
<i>Abrus precatorius</i> Linn.	Papilionaceae	Indian liquorice, chirmiti	Menopausal symptoms, cough	L	Oil	[82]
<i>Acacia catechu</i> Willd.	Fabaceae	Mimosa catechu	Diarrhea, Osteoarthritis	R	Extract	[83]
<i>Acalypha indica</i> Linn.	Euphorbiaceae	Kuppu, Arittmanjarie	Asthma, Pneumonia	L	Juice	[84]
<i>Acanthus illicifolius</i> Linn.	Acanthaceae	Sea holly, Moranna harikusa	Paralysis, wounds	L	Extract	[82]
<i>Achillea millefolium</i> Linn.	Compositae	Rojmari, bloodwort, arrow-root	Parkinson's disease	H	Extract	[85]
<i>Achyranthus aspera</i> Linn.	Amaranthaceae	Chirchitta, aghada, prickly chaff-flower	Piles, kidney stone	R	Infusion	[86]
<i>Actaea spicata</i> Linn.	Ranunculaceae	Baneberry, grapewort	Inflammation, lumbago	R	Powder	[82]
<i>Adansonia digitata</i> Linn.	Malvaceae	Gorakh amla	Antitussive, antipyretic	L	Poultices	[84]
<i>Aegel marmolosa</i> Corr.	Rutaceae	Stone apple, bael	Anticancer	F	Juice	[88]
<i>Ailanthus excels</i> Roxb.	Simaroubaceae	Indian tree of heaven	Bronchitis	L	Oil, extract	[83]
<i>Allium cepa</i> Linn.	Liliaceae	Onion, palandu	Asthma, inflammatory disorders	Bu	Paste	[84]
<i>Allium sativum</i> Linn.	Liliaceae	Garlic, lasun	Rheumatism	S	Oil	[87]
<i>Alstonia scholaris</i> R.Br.	Apocynaceae	Datyuni, saptaparna	Malaria, jaundice	Mj	Juice	[89]
<i>Althaea rosea</i> Cav.	Malvaceae	Hollyhock, round dock	Inflammation, constipation	Fl	Oil	[82]
<i>Ammannia baccifera</i> Linn.	Lythraceae	Dadmari, agni-garva	Typhoid fever	L	Blisters	[90]
<i>Amorphophallus campanulatus</i> Roxb.	Aracea	Zamikand, kandula kandvardhana	Liver disease, piles	S	Oil	[82]
<i>Apium graveolens</i> Linn.	Umbellifaeae	Ajmoda, celery	Gout	R	Decoction	[85]
<i>Argyrea speciosa</i> Sweet.	Convulvulaceae	Elephant creeper	Ulcers, diabetes	R	Powder	[84]
<i>Aristolochia bracteata</i> Linn.	Aristolochiaceae	Birthworts, pipevines	Tumors, malaria	Wh	Extract	[92]
<i>Aristolochia serpentaria</i> Linn.	Aristolochiaceae	Virginian snake root	Diuresis	R	Infusion	[91]
<i>Asparagus racemosus</i> Willd.	Liliaceae	Shatavari	Infertility	R	Oil	[87]
<i>Atropa belladonna</i> Linn.	Solanaceae	Black cherry, sagangur	Stomach ulcer	R, L	Extract	[82]
<i>Azadirachta indica</i> A. Juss.	Meliaceae	Bakayan, Indian lilac, balnimb	Anti-fungal	L	Decoction	[82]
<i>Azima tetracantha</i> Lam.	Salvadoraceae	Kundali	Rheumatism	L, R	Decoction	[84]
<i>Bacopa monnieri</i> Penell.	Plantaginaceae	Brahmi	Constipation	Wh	Extract	[93]
<i>Barosma crenulata</i> Hook.	Rutaceae	Bucchu, buku	Rheumatism	L	Powder	[91]
<i>Bauhinia racemosa</i> Lam.	Fabaceae	Bidi leaf tree, kachnal	Diabetes	B	Extract	[88]
<i>Bauhinia tomentosa</i> Linn.	Fabaceae	Yellow bell orchid	Liver inflammation	L	Infusion	[94]
<i>Bidens pilosa</i> Linn.	Compositae	Black jack, phutium	Cancers, wounds	Sh	Young shoots	[82]
<i>Blumea ripens</i> DC.	Asteraceae	Red stink wood	Skin wound	S	Oil	[83]
<i>Bula alba</i> Linn.	Cupuliferae	White birch bark	Rheumatism	L	Extraction	[87]
<i>Boerhaavia diffusa</i> Linn.	Nyctagineae	Punamava, thikri	Anti dengue	R	Paste	[95]
<i>Boucerosia aucheriana</i> Dcne.	Asclepiadaceae	Charungli, chungi pamanke	Skin disease	St, Wh	Juice	[82]
<i>Borassus flabellifer</i> Linn.	Arecaceae	Toody palm, sugar palm	Gastritis disorders	F	Juice	[88]
<i>Calotropis procera</i> R.Br.	Asclepiadaceae	Madar	Helminthiasis	R-B	Extract	[91]
<i>Cardiospermum halicacabum</i> Linn.	Sapindaceae	Balloon vine, winter cherry	Chronic bronchitis	R, L	Decoction	[98]
<i>Carissa carandas</i> Linn.	Apocynaceae	Karamardaka	Constipation	S	Extract	[83]
<i>Carissa spinarum</i> Linn.	Apocynaceae	Karunda, gama	Epilepsy	R	Extract	[82]
<i>Carthamus tinctorius</i> Linn.	Compositae	Wild saffron, kamalottara	Stroke	Fl	Hot infusion	[87]
<i>Cassia fistula</i> Linn.	Caesalpiniceae	Sonhali, nripadruma	Edema	B, L	Paste	[84]
<i>Cassia sophora</i> Linn.	Caesalpiniceae	Bas-ki-kasunda	Cough	L	Infusion	[87]
<i>Cassia tora</i> Linn.	Fabaceae	Charota, taga	Flatulence	L	Infusion	[83]
<i>Cadrea toona</i> Roxb.	Meliaceae	Toona, khusing	Menstrual Disorders	B	Infusion	[87]
<i>Cedrus deodara</i> Lou Don.	Coniferae	Deodar, kilan, geyar	Microbial Infection	W	Oil	[82]
<i>Cedrus libani</i> Barrel	Coniferae	Deodar, devadaru	Toothache	Gm	Gum	[87]
<i>Celastrus paniculata</i> Willd.	Calatraceae	Malakanguni, vanhiruchi	Epilepsy	S	Decoction	[84]

<i>Celosia argentea</i> Linn.	Amaranthaceae	Paanai keerai	Eye problems	L	Decoction	[94]
<i>Centella asiatica</i> Urban.	Mackinlayaceae	Gotu kola	Atopic dermatitis	St	Extract	[99]
<i>Cephaelis ipecacuanha</i> A.Rich.	Rubiaceae	Poaya	Cancer	R	Extract	[91]
<i>Ephedra vulgaris</i> Rich.	Ephedraceae	Khanda, ma-hung	Nasal congestion	Be	Decoction	[102]
<i>Euphorbia antiquorum</i> Linn.	Euphorbiaceae	Triangular spurge, Tidhara, vajratundi	Dropsy	Br	Gum, milky juice	[103]
<i>Ficus bengalensis</i> Linn.	Urticaceae	Banyan tree, sriksha	Dysentery	S, F	Juice	[104]
<i>Ficus religiosa</i> Linn.	Urticaceae	Pippala, peepul tree	Gonorrhea	B	Decoction, oil	[87]
<i>flendarussa vulgaris</i> Nees.	Acanthaceae	Nili-nargandi, kala-bashimb	Chronic rheumatism	L	Infusion	[87]
<i>Jatropha curcas</i> Linn.	Euphorbiaceae	Jangli-erandi, angula-leaved physic nut	Rheumatic and muscular pain	S	Oil	[106]
<i>Justica gendaruusa</i> Burm.	Acanthaceae	Nilinargandi, kapika, bhutakeshi	Hepatic injuries	L	Decoction	[107]
<i>Lawsonia alba</i> Linn.	Lythraceae	Heena, mendhi, mehndi	Ulcers, ophthalmic disorder	L	Paste	[108]
<i>Leucas aspera</i> Spreng.	Labiatae	Chotahalkusa, tamba,	Psoriasis	L	Juice	[109]
<i>Linum usitatissimum</i> Linn.	Linaceae	Lins, uma, tisi	Gout, obesity	S	Poultice	[110]
<i>Merremia tridentata</i> Hallier.	Convolvulaceae	Prasarini	Hemorrhoids	Wh	Extract	[111]
<i>Murray koenigii</i> Linn.	Rutaceae	Bristly bryoni	Edema	L	Powder	[94]
<i>Myristica fragrans</i> Hoult.	Myristaceae	Nutmeg, jati-phalam., jaiphal	Rheumatoid Arthritis	S	Oil	[84]
<i>Myristica malabarica</i> Lamk.	Myristaceae	Malabar nutmeg, malati, kamuk	Bronchitis	S	Embrocation	[87]
<i>Myropyrum similacifolium</i> Blume.	Oleaceae	Chatura-mallikei	Cough	L	Extract	[87]
<i>Myrtus caryophyllus</i> Linn.	Myrtaceae	Cloves, lavangaha, laung	Rheumatic pain	F	Oil	[87]
<i>Myrtus communis</i> Linn.	Myrtaceae	Myrtle, murad	Pulmonary and Skin disease	L	Oil	[87]
<i>Naregamia alata</i> W. & A.	Meliaceae	Goanese ipecacuanha, amlavalli	Eczema	Wh	Extract	[82]
<i>Nicotiana tabacum</i> Linn.	Solanaceae	Tobacco, tambaku, tamrakuta	Respiratory tract disease	L	Decoction	[87]
<i>Nyctanthus arbor-tristis</i> Linn.	Oleaceae	Night jasmine, siharu, parijata	Rheumatoid Arthritis	L	Infusion	[87]
<i>Ocimum gratissimum</i> Linn.	Labiatae	Shrubby basil, ramtulasi	Inflammation, diabetes	Wh	Fumigations	[84]

L: Leaves, R: Roots, H: Herb, Wh: Whole plant, Rh: Rhizome, B: Bark, F: Fruit, Bu: Bulb, S: Seed, T: Tubers, Fl: Flowers, Mj: Milky juice, G: Grass, St: Stems, W: Wood, Be: Berries, Gm: Gum, K: Kernel, Sh: Shoot, C: Camphor, Rs: Resin, Br: Branches, Sg: Stigmas, Sp: Spores, Bt: Bracts, Sbe: Strawberries, Rbe: Ripeberries, Gr: Grain, C: Currants, O: Oil, P: Pulse, Sr: Sarocarp, Nt: Nuts, Al pt: Aerial parts, Ug pt: Underground parts-Ug pt

AYURVEDIC PRODUCTS:

1.Dabur India Ltd.

- -Product: Rheumartho
- -Formulation: Oil/Capsule
- -Use: Relieves joint pain, inflammation and stiffness

2.Patanjali Ayurved Ltd.

- -Product: Joint Care
- -Formulation: Oil/Capsule
- -Use: Reduces joint pain, inflammation and stiffness

3.Himalaya Wellness

- -Product: Rimalaya
- -Formulation: Tablet/Capsule
- -Use: Relieves joint pain, inflammation and stiffness

HERBAL SUPPLEMENT:**1.Nature's Bounty**

- -Product: Turmeric Curcumin
- -Formulation: Capsule
- -Use: Anti-inflammatory, antioxidant properties

2.Gaia Herbs

- -Product: Turmeric Supreme
- -Formulation: Capsule
- -Use: Anti-inflammatory, antioxidant properties

CONCLUSION:

Many tribal and rural communities around the world use traditional medicines to treat arthritis. Currently, research into traditional medicine's anti-arthritic properties has produced and examined a wide range of herbal treatments used for this purpose. The data acquired from many sources aids in both the preservation of traditional indigenous knowledge and the identification of possible chemicals with encouraging anti-arthritic properties. The information obtained from the data gives details on the tested extracts' toxicity profile and mode of action. As a result, this review article was written to list the plants and their parts that have been traditionally used to cure arthritis up to 2013. Furthermore, to the best of our knowledge, previous reviews on arthritis therapy do not contain the most recent information on novel plant species or polyherbal formulations.

In order to achieve complete remission or at least a notable decrease in symptoms and clinical indicators, the ultimate goal of managing RA is to begin an aggressive medication regimen. The findings of the studies made it easier to comprehend the pathophysiological pathways and created novel treatment strategies, making RA a treatable condition. Many RA patients, nonetheless, are still not responding to the drugs that are now prescribed. There is still not enough information to fully control the illness, which emphasises the need for new medications and a stronger emphasis on personalised medicine.

REFERENCES:

1. Harris E.D. Rheumatoid arthritis: Pathophysiology and implications for therapy. *N. Engl. J. Med.* 1990; 322:1277-1289.
2. Patwardhan S.K., Bodas K.S., Gundewar S.S. Coping with arthritis using safer herbal options. *Int. J. Pharm. Pharm. Sci.* 2010; 2(1):2-11.
3. Lubberts E et al Adult rheumatoid arthritis - a review. *International journal of pharmaceutical research and development* 2010; 2(2): 1-9, Joosten LA, Oppers B, Berselaar V L, Coenen-de Roo CJ, Kolls JK et al IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. *J Immunol* 2001; 167(2): 1004-13.
4. Gracie JA, Forsey RJ, Chan WL, Gilmour A, Leung BP, Greer MR et al A proinflammatory role for IL-18 in rheumatoid arthritis. *J Clin Invest* 1999; 104(10): 1393-401
5. Ramalingam K, Mathiyalagan A, Subramanian S and Bharathi Rajan UD, Musculo-skeletal joint inflammatory diseases - new vistas from animal model studies – An overview, *J Biochem Tech*, 2009, 1(4), 108-113.
6. Tandon V, Gupta RK. Histomorphological changes induced by Vitex negundo in albino rats. *Indian J Pharmacol* 2004; 36:176-7.
7. Vispute S, Khopade A. Glycyrrhiza glabra Linn. - "Klitaka": A review. *Int J Pharm Bio Sci* 2011; 2:42-51.
8. Badami S, Moorkoth S, Suresh B. Caesalpinia sappan a medicinal and dye yielding plant. *Nat Prod Rad* 2004; 3:75-82.
9. Kalaria P, Gheewala P, Chakraborty M, Kamath J. A phytopharmacological review of Alstonia scholaris: A panoramic herbal medicine. *IJRAP* 2012; 3:367-371.
10. Sudha K, Mathanghi SK. Traditional underutilized green leafy vegetables and its curative properties. *Int J Pharm* 2012; 2:786-93.
11. Singh V, Patel H, Suvagiya V, Singh K. Some traditionally used antiarthritic herbs a review. *Int Res J Pharm* 2011; 2:43-5.
12. Kiran D, Rohilla A, Rohilla S, Khan MU. Phyllanthus Amaru's: An ample therapeutic potential herb. *Int J Res Ayur Pharm* 2011; 2:1096-9.
13. Thirumal M, Vadivelan R, Kishore G, Brahmaji VS. Aristolochia bracteolata: An overview on pharmacognostical, phytochemical and pharmacological properties. *Earth J* 2012; 1:66-78.
14. Kalita S, Kumar G, Karthik L, Rao BV. A review on medicinal properties of Lantana camara Linn. *Res J Pharm Technol* 2012; 5:711-5.
15. Jeoung BR, Lee KD, Na CS, Kim YE, Kim B, Kim YR. Ganghwaljetongyeum, an anti-arthritic remedy, attenuates synovial cell proliferation and reduces the production of proinflammatory mediators in macrophages: The therapeutic effect of GHJTY on rheumatoid arthritis. *BMC Complement Altern Med* 2013; 13:47.
16. Patel D, Kaur G, Sawant MG, Deshmukh P. Herbal medicine- A natural cure to arthritis. *Indian J Nat Prod Res* 2012; 4:27-35.
17. Patel SS, Shah PV. Evaluation of anti-inflammatory potential of the multidrug Herbo mineral formulation in male Wistar rats against rheumatoid arthritis. *J Ayurveda Integr Med* 2013; 4:86-93.
18. Singh S, Nair V, Gupta YK. Antiarthritic activity of majoon suranjan (a polyherbal Unani formulation) in rat. *Indian J Med Res* 2011; 134:384-8.
19. Asad M, Prasad K, Thomas L, Kamath JV. Evaluation of analgesics and anti-inflammatory activity of Sudard, A poly-herbal formulation. *Iran J Pharmacol Ther* 2007; 6:71-5.
20. Shen X, Li C, Zhao H, Li S, Chen J, Kobayashi Y, et al. Inhibitory effects of a traditional Chinese herbal formula TBL-II on type II collagen induced arthritis in mice. *J Ethnopharmacol* 2011; 134:399-405.

21. 21.Zhang RX, Fan AY, Zhou AN, Moudgil KD, Ma ZZ, Lee DY, et al. Extract of the Chinese herbal formula Huo Luo Xiao Ling Dan inhibited adjuvant arthritis in rats. *J Ethnopharmacol* 2009; 121:366-71.
22. 22.Kohler BM € et al. Current therapeutic options in the treatment of rheumatoid arthritis. *J Clin Med* 2019; 8: 938.
23. Batko B et al. Management of rheumatoid arthritis in Poland– where daily practice might not always meet evidence-based guidelines. *Arch Med Sci* 2019; 15.
24. Avina-Zubieta ~ JA et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. *Arthritis Care Res* 2008; 59: 1690–1697.
25. 25.Paschke S et al. technical advance: Inhibition of neutrophil chemotaxis by colchicine is modulated through viscoelastic properties of subcellular compartments. *J Leukoc Biol* 2013; 94: 1091–1096.
26. 26.Gabriel SE et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. *Arthritis Rheum* 2003; 48: 54–58.
27. 27.Crowson CS et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. *Arthritis Rheum* 2011; 63: 633–639.
28. 28.Souto AL et al. Anti-inflammatory activity of alkaloids: an update from 2000 to 2010. *Molecules* 2011; 16: 8515–8534
29. 29.Marks WH, Tripterygium Wilfordii Hook F. versus Sulfasalazine in the treatment of rheumatoid arthritis: a well-designed clinical trial of a botanical demonstrating effectiveness. *Fitoterapia* 2011; 82: 5–87
30. 30.Moelants EA et al. Regulation of TNF-alpha with a focus on rheumatoid arthritis. *Immunol Cell Biol* 2013; 91: 393–401.
31. 31.Ghisletti S et al. 17b-estradiol inhibits inflammatory gene expression by controlling NF-jB intracellular localization. *Mol Cell Biol* 2005; 25: 2957– 2968.
32. 32.Iqbal J, Zaidi M. Understanding oestrogen action during menopause. *Endocrinology* 2009; 150: 3443–3445.
33. 33.Rubtsov AV et al. Genetic and hormonal factors in female-biased autoimmunity. *Autoimmune Rev* 2010; 9: 494–498.
34. 34.Liu Y et al. Hyperprolactinemia is associated with a high prevalence of serum autoantibodies, high levels of inflammatory cytokines and an abnormal distribution of peripheral B-cell subsets. *Endocrine* 2019; 64: 648–656.
35. 35.McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. *N Engl J Med* 2011; 365: 2205–2219.
36. 36.Firestein GS, McInnes IB. Immunopathogenesis of rheumatoid arthritis. *Immunity* 2017; 46: 183–196.
37. 37.Pradhan VD et al. Study of PTPN22 1858C/T polymorphism in rheumatoid arthritis patients from Western India. *Indian J Rheumatol* 2012; 7: 130–134.
38. 38.Li S et al. Microbial infection and rheumatoid arthritis. *J Clin Cell Immunol* 2013; 4: 174.
39. 39.Mahabadi M et al. Detection of Epstein-Barr virus in synovial fluid of rheumatoid arthritis patients. *Electron Physician* 2016; 8: 2181–2186.
40. 40.Scher JU et al. Microbiome in inflammatory arthritis and human rheumatic diseases. *Arthritis Rheumatol* 2016; 68: 35–45.
41. 41.Lahiri M et al. Modifiable risk factors for RA: prevention, better than cure? *Rheumatology* 2011; 51: 499–512
42. 42.Sparks JA, Karlson EW. The roles of cigarette smoking and the lung in the transitions between phases of preclinical rheumatoid arthritis. *Curr Rheumatol Rep* 2016; 18: 15
43. 43.Rindfleisch JA and Muller D Diagnosis and Management of Rheumatoid Arthritis. *American Family Physician* 2005; 72(6): 1037-1047.
44. 44.A committee of the American Rheumatism Association, diagnostic criteria for rheumatoid arthritis 1958 revision *Annals of rheumatoid diseases EULAR journal* 1959; 18(1):49–53.
45. Keefe F., Bonk V. Psychological assessment of pain in patients having rheumatic diseases. *Rheumat. Dis. Clinics North Am.* 1999; 25:81–103.
46. http://www.rheumatology.org/practice/clinical/patients/diseases_and_conditions/ra.pdf
47. 47.Ropes M.W., Bennet G.A., Cobb S., Jacox R., Jessar R.A. Revision of diagnostic criteria for rheumatoid arthritis. *Bull. Rheu. Dis.* 1958; 9:175- 176.
48. 48.Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S. et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis & Rheumatism Arthritis & Rheumatism-Arthritis Care & Research* 1988; 31(3):315-324.
49. 49.Roberts-Thomson, P.J.; Jones, M.E.; Walker, J.G.; Macfarlane, J.G.; Smith, M.D.; Ahern, M.J. Stochastic processes in the causation of rheumatic disease. *J. Rheumatol.* **2002**, 29, 2628–2634.
50. 50.Petrovská, N.; Prajzlerová, K.; Vencovský, J.; Šenolt, L.; Filková, M. The pre-clinical phase of rheumatoid arthritis: From risk factors to prevention of arthritis. *Autoimmun. Rev.* **2021**, 20, 102797.
51. 51.Macgregor, A.J.; Snieder, H.; Rigby, A.S.; Koskenvuo, M.; Kaprio, J.; Aho, K.; Silman, A.J. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. *Arthritis Rheum.* **2000**, 43, 30–37.
52. 52.Van der Helm-van Mil, A.H.M.; Verpoort, K.N.; Breedveld, F.C.; Huizinga, T.W.J.; Toes, R.E.M.; Vries, R.R.P. The HLA–DRB1 shared epitope alleles are primarily a risk factor for anti–cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. *Arthritis Rheum.* **2006**, 54, 1117–1121.
53. 53.Ding, B.; Padyukov, L.; Lundström, E.; Seielstad, M.; Plenge, R.M.; Oksenberg, J.R.; Gregersen, P.K.; Alfredsson, L.; Klareskog, L. Different patterns of associations with anti–citrullinated protein antibody–positive and anti–citrullinated protein antibody– negative rheumatoid arthritis in the extended major histocompatibility complex region. *Arthritis Rheum.* **2009**, 60, 30–38.
54. 54.Kokkonen, H.; Johansson, M.; Innala, L.; Jidell, E.; Rantapää-Dahlqvist, S. The PTPN221858C/T polymorphism is associated with anti-cyclic citrullinated peptide antibody-positive early rheumatoid arthritis in northern Sweden. *Arthritis Res. Ther.* **2007**, 9, 1–7.

55. 55.Källberg, H.; Padyukov, L.; Plenge, R.M.; Rönnelid, J.; Gregersen, P.K.; van der Helmvan Mil, A.H.M.; Toes, R.E.M.; Huizinga, T.W.; Klareskog, L.; Alfredsson, L.; et al. Gene-Gene and Gene-Environment Interactions Involving HLA-DRB1, PTPN22, and Smoking in Two Subsets of Rheumatoid Arthritis. *Am. J. Hum. Genet.* **2007**, *80*, 867–875.
56. 56.Zhang, X.; Li, W.; Zhang, X.; Zhang, X.; Jiang, L.; Guo, Y.; Wang, X. Association between polymorphism in TRAF1/C5 gene and risk of rheumatoid arthritis: A meta-analysis. *Mol. Biol. Rep.* **2013**, *41*, 317–324.
57. 57.Sigurdsson, S.; Padyukov, L.; Kurreeman, F.A.S.; Liljedahl, U.; Wiman, A.-C.; Alfredsson, L.; Toes, R.; Rönnelid, J.; Klareskog, L.; Huizinga, T.W.J.; et al. Association of a haplotype in the promoter region of the interferon regulatory factor 5 gene with rheumatoid arthritis. *Arthritis Rheum.* **2007**, *56*, 2202–2210.
58. 58.Vessey, M.P.; Villard-Mackintosh, L.; Yeates, D. Oral contraceptives, cigarette smoking and other factors in relation to arthritis. *Contraception* **1987**, *35*, 457–464.
59. 59.Liao, K.P.; Alfredsson, L.; Karlson, E.W. Environmental influences on risk for rheumatoid arthritis. *Curr. Opin. Rheumatol.* **2009**, *21*, 279–283.
60. 60.Ishikawa, Y.; Terao, C. The impact of cigarette smoking on risk of rheumatoid arthritis: A narrative review. *Cells* **2020**, *9*, 475.
61. 61.Linn-Rasker, S.P.; van der Mil, A.H.M.H.; van Gaalen, F.A.; Kloppenburg, M.; de Vries, R.R.P.; le Cessie, S.; Breedveld, F.C.; Toes, R.E.M.; Huizinga, T.W.J. Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles. *Ann. Rheum. Dis.* **2006**, *65*, 366–371.
62. 62.Padyukov, L.; Silva, C.; Stolt, P.; Alfredsson, L.; Klareskog, L. A gene–environment interaction between smoking and shared epitope genes in HLA–DR provides a high risk of seropositive rheumatoid arthritis. *Arthritis Rheum.* **2004**, *50*, 3085–3092.
63. 63.Hedström, A.K.; Klareskog, L.; Alfredsson, L. Exposure to passive smoking and rheumatoid arthritis risk: Results from the Swedish EIRA study. *Ann. Rheum. Dis.* **2018**, *77*, 970–972.
64. 64.Mehri, F.; Jenabi, E.; Bashirian, S.; Shahna, F.G.; Khazaei, S. The association between occupational exposure to silica and risk of developing rheumatoid arthritis: A meta-analysis. *Saf. Health Work* **2020**, *11*, 136–142.
65. 65.Alaya, Z.; Braham, M.; Aissa, S.; Kalboussi, H.; Bouajina, E. A case of Caplan syndrome in a recently diagnosed patient with silicosis: A case report. *Radiol. Case Rep.* **2018**, *13*, 663–666.
66. 66.Jin, J.; Li, J.; Gan, Y.; Liu, J.; Zhao, X.; Chen, J.; Zhang, R.; Zhong, Y.; Chen, X.; Wu, L.; et al. Red meat intake is associated with early onset of rheumatoid arthritis: A cross-sectional study. *Sci. Rep.* **2021**, *11*, 1–7.
67. 67.Pattison, D.J.; Harrison, R.A.; Symmons, D.P.M. The role of diet in susceptibility to rheumatoid arthritis: A systematic review. *J. Rheumatol.* **2004**, *31*, 1310–1319.
68. 68.Karlson, E.W.; Mandl, L.A.; Aweh, G.N.; Grodstein, F. Coffee consumption and risk of rheumatoid arthritis. *Arthritis Rheum.* **2003**, *48*, 3055–3060.
69. 69.Mehta, B.; Pedro, S.; Ozen, G.; Kalil, A.; Wolfe, F.; Mikuls, T.; Michaud, K. Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: A US national cohort study. *RMD Open* **2019**, *5*, e000935.
70. 70.Feder, H.M.J.; Johnson, B.J.B.; O’Connell, S.; Shapiro, E.D.; Steere, A.C.; Wormser, G.P. A critical appraisal of “chronic lyme disease”. *N. Engl. J. Med.* **2009**, *357*, 1422–1430.
71. 71.Perricone, C.; Ceccarelli, F.; Saccucci, M.; di Carlo, G.; Bogdanos, D.P.; Lucchetti, R.; Pilloni, A.; Valesini, G.; Polimeni, A.; Conti, F. Porphyromonas gingivalis and rheumatoid arthritis. *Curr. Opin. Rheumatol.* **2019**, *31*, 517–524.
72. 72.Firestein, G.S.; McInnes, I.B. Immunopathogenesis of rheumatoid arthritis. *Immunity* **2017**, *46*, 183–196.
73. 73.Curran, A.M.; Naik, P.; Giles, J.T.; Darrah, E. PAD enzymes in rheumatoid arthritis: Pathogenic effectors and autoimmune targets. *Nat. Rev. Rheumatol.* **2020**, *16*, 301–315.
74. 74.Scherer, H.U.; Häupl, T.; Burmester, G.R. The etiology of rheumatoid arthritis. *J. Autoimmun.* **2020**, *110*, 102400.
75. 75.Damerau, A.; Gaber, T. Modeling rheumatoid arthritis in vitro: From experimental feasibility to physiological proximity. *Int. J. Mol. Sci.* **2020**, *21*, 7916.
76. 76.van Dongen, V.; Holoshitz, J. HLA-disease associations in rheumatoid arthritis. *Rheum. Dis. Clin. North Am.* **2017**, *43*, 363–376.
77. 77.Frauwirth, K.A.; Thompson, C.B. Activation and inhibition of lymphocytes by costimulation. *J. Clin. Investig.* **2002**, *109*, 295–299.
78. 78.Isaacs, J.D. Therapeutic T-cell manipulation in rheumatoid arthritis: Past, present and future. *Rheumatology* **2008**, *47*, 1461–1468.
79. 79.Stavnezer, J.; Guikema, J.E.J.; Schrader, C.E. Mechanism and regulation of class switch recombination. *Annu. Rev. Immunol.* **2008**, *26*, 261–292.
80. 80.Ingegnoli, F.; Castelli, R.; Gualtierotti, R. Rheumatoid factors: Clinical applications. *Dis. Markers* **2013**, *35*, 727–734.
81. 81.Yu, H.C.; Lu, M.C. The roles of anti-citrullinated protein antibodies in the immunopathogenesis of rheumatoid arthritis. *Tzu-Chi Med. J.* **2019**, *31*, 5–10.
82. 82.Kirtikar KR, Basu BD. Indian Medicinal Plants. 2nd ed. Utranchal, India: Oriental Enterprises; 2003.
83. 83.Pushpan R, Nishteswar K, Kumari H. Anti-arthritis natural medicine: Classical ayurveda and ethnomedical source. *BMC Musculoskeletal Disord* **2013**; *1*:32-40
84. 84.Patel D, Kaur G, Sawant MG, Deshmukh P. Herbal medicine- A natural cure to arthritis. *Indian J Nat Prod Res* **2012**; *4*:27-35
85. 85.Mikaili P, Shayegh J, Asghari MH. Review on the indigenous use and ethnopharmacology of hot and cold natures of phytochemicals in the Iranian traditional medicine. *Asian Pac J Trop Med*, **2012**; *2*:S1189-93
86. 86.Neogi NC, Rathor RS, Shrestha AD, Banerjee DK. Studies on the anti-inflammatory and anti-arthritis activity of Achyranthine. *Indian J Pharmacol* **1969**; *1*:37-47.
87. 87.Nadkarni KM. Indian Materia Medica. Vol. I. Bombay, India: Poupular Pakashan Pvt. Ltd; 2009.
88. 88.Singh V, Patel H, Suvagiya V, Singh K. Some traditionally used antiarthritic herbs a review. *Int Res J Pharm* **2011**; *2*:43-5.

89. 89.Arulmozhi S, Mazumder PM, Sathiyarayanan L, Ashok P. Antiarthritic and antioxidant activity of leaves of *Alstonia scholaris* Linn R Br. Eur J Integr Med 2011;3:e83-90
90. 90.Tripathy S, Pradhan D, Anjana M. Anti-inflammatory and antiarthritic potential of *Ammania baccifera* Linn. Int J Pharm Bio Sci 2010;1:1-7
91. 91.Bentley R, Trimen H. Medicinal Plants. Reprint Indian Edition. Delhi, India: Asiatic Publishing House; 2002.
92. 92.Chitme RH, Patel PN. Antiarthritis activity of *Aristolochia bracteata* extract in experimental animals. Open Natl Pro J 2009;2:6-15.
93. 93.Vijayan V, Shyni GL, Helen A. Efficacy of *Bacopa monniera* (L.) Wettst in alleviating lysosomal instability in adjuvant-induced arthritis in rats. Inflammation 2011;34:630-8.
94. 94.Sudha K, Mathanghi SK. Traditional underutilized green leafy vegetables and its curative properties. Int J Pharm 2012;2:786-93.
95. 95.Dapurkar KV, Sahu KG, Sharma H, Meshram S, Rai G. Anti-arthritis activity of roots extract of *Boerhaavia Diffusa* in adjuvant induced arthritis rats. Sch Acad J Pharm 2013;2:107-9
96. 96.Mishra NK, Bstia S, Mishra G, Chowdary AK, Patra S. Anti-arthritis activity of *Glycyrrhiza glabra*, *Boswellia serrata* and their synergistic activity in combined formulation studied in Freund's adjuvant induced arthritic rats. J Pharm Educ Res 2011;2:92-8
97. 97.Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreaskos E, Mechoulam R, et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritis therapeutic in murine collageninduced arthritis. Proc Natl Acad Sci U S A 2000;97:9561-6.
98. 98.Ramachandran J, Thilagar S, Angappan R, Lakshmanan DK. Antiarthritic activity of the Indian leafy vegetable *Cardiospermum halicacabum* in Wistar rats and UPLC–QTOF–MS/MS identification of the putative active phenolic components. Inflamm Res 2013;62:115-26.
99. 99.Chippada CS, Vangalapati M. Antioxidant, an anti-inflammatory and anti-arthritis activity of *Centella asiatica* extracts. J Chem Biol Physical Sci 2011;1:260-9.
100. 100.Srivastava S, Singh P, Jha KK, Mishra G, Srivastava S, Khosa RL. Evaluation of anti-arthritis potential of the methanolic extract of the aerial parts of *Costus speciosus*. J Ayurveda Integr Med 2012;3:204-8.
101. 101.Murugananthan G, Mohan S. Anti-inflammatory and anti-arthritis activities of *Delonix elata* bark extracts. Int J Res Ayur Pharm 2011;2:1819-21.
102. 102.Yeom MJ, Lee HC, Kim GH, Lee HJ, Shim I, Oh SK, et al. Anti-arthritis effects of *Ephedra sinica* STAPF herb-acupuncture: Inhibition of lipopolysaccharide-induced inflammation and adjuvant-induced polyarthritis. J Pharmacol Sci 2006;100:41-50.
103. 103.Harpalani AN, Taranalli AD, Otari KV, Karadi RV, Shete RV. An antiinflammatory and anti-arthritis potential of aqueous and alcoholic extract of *Euphorbia antiquorum* Linn. Pharmacologyonline 2011;2:287-98.
104. 104.Manocha N, Chandra SK, Sharma V, Sangameswaran B, Saluja M. Anti-rheumatic and antioxidant activity of extract of stem bark of *Ficus bengalensis*. Res J Chem Sci 2011;1:2-8.
105. 105.Mehta A, Sethiya NK, Mehta C, Shah GB. Anti-arthritis activity of roots of *Hemidesmus indicus* R.Br. (Anantmul) in rats. Asian Pac J Trop Med 2012;5:130-5.
106. 106.Silva CR, Fröhlich JK, Oliveira SM, Cabreira TN, Rossato MF, Trevisan G, et al. The antinociceptive and anti-inflammatory effects of the crude extract of *Jatropha isabellei* in a rat gout model. J Ethnopharmacol 2013;145:205-13.
107. 107.Paval J, Kaitheri SK, Potu BK, Govindan S, Kumar RS, Narayanan SN, et al. Anti-arthritis potential of the plant *Justicia gendarussa* Burm F. Clinics (Sao Paulo) 2009;64:357-62.
108. 108.Kore KJ, Shete RV, Desai NV. Anti-Arthritis activity of hydroalcoholic extract of *Lawsonia Innermis*. Int J Drug Dev Res 2011;3:217-24.
109. 109.Kripa KG, Chamundeeswari D, Thanka J, Uma Maheswara Reddy C. Modulation of inflammatory markers by the ethanolic extract of *Leucas aspera* in adjuvant arthritis. J Ethnopharmacol 2011;134:1024-7.
110. 110.Kaithwas G, Majumdar DK. Therapeutic effect of *Linum usitatissimum* (flaxseed/linseed) fixed oil on acute and chronic arthritic models in albino rats. Inflammopharmacology 2010;18:127-36.
111. 111.Kamalutheen M, Gopalkrishnan M, Ismail TS. Anti-inflammatory and anti-arthritis activities of *Merremia tridentata* (L.) Hall. E J Chem 2009;6:943-8.